Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Bread Financial price target raised to $68 from $62 at RBC Capital
RBC Capital analyst Jon Arfstrom raised the firm’s price target on Bread Financial (BFH) to $68 from $62 and keeps a Sector Perform rating on ...
The Real Good Food Company Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
The decision to voluntarily delist and deregister from the SEC was made after careful consideration by the Board of Directors of various factors, including Nasdaq’s announcement that it had suspended ...
The Real Good Food Company intends to delist from Nasdaq and deregister with the SEC
The Real Good Food Company (RGF) announced on Thursday its intention to voluntarily delist its common stock from the Nasdaq ...
Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...
Keefe raises Renasant stock price target to $46, keeps Outperform rating
Keefe, Bruyette & Woods analyst Catherine Mealor increased the price target on Renasant Corp (NYSE: NYSE:RNST) to $46 from ...